NEW YORK (GenomeWeb) — Qiagen said Wednesday after the close of the market that its artus CMV RGQ MDx kit for human cytomegalovirus has been approved by the US Food and Drug Administration under a full premarket approval.

The test runs on Qiagen's Rotor-Gene Q MDx real-time PCR platform, which was cleared by the FDA in 2012 and is part of the QIAsymphony family of modular, automated instruments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.